Details for: REMICADE
Company: JANSSEN INC
| DIN | DIN name | Active Ingredient(s) | Strength | Dosage Form | Route of Administration |
|---|---|---|---|---|---|
| 02244016 | REMICADE | INFLIXIMAB | 100 MG / VIAL | POWDER FOR SOLUTION | INTRAVENOUS |
Summary Reports
Summary Safety Review - REMICADE (infliximab) - Evaluating for the Risk of Cancer (Lymphoma, Hepatosplenic T-Cell Lymphoma, and Leukemia)
Summary Safety Review - Tumour necrosis factor (TNF) blockers - Glioblastoma (brain tumour)
Summary Safety Review - REMICADE (infliximab) - Assessing the potential risk of a blistering skin condition known as linear IgA bullous dermatosis
Summary Safety Review - Tumour necrosis factor (TNF) blockers - Glioblastoma (brain tumour)
Summary Safety Review - REMICADE (infliximab) - Assessing the potential risk of a blistering skin condition known as linear IgA bullous dermatosis
Consumer Information
The Consumer Information is not yet available in the Drug and Health Product Register. Try searching on the active ingredient(s) to find other similar products.